AACR 2025 - Non–Small Cell Lung Cancer

Promising Efficacy and Manageable Safety of Zongertinib in HER2-Mutant NSCLC: Insights From the Beamion LUNG-1 Trial

The Beamion LUNG-1 study explored zongertinib as a promising HER2-targeted therapy for advanced or metastatic non–small cell lung cancer (NSCLC). Read More ›

Videos

Efficacy and Safety of Tiragolumab Plus Atezolizumab in PD-L1–High NSCLC: Insights From the SKYSCRAPER-01 Trial

By Martin F. Dietrich, MD, PhD

AACR 2025 - Non–Small Cell Lung Cancer

SKYSCRAPER-01 evaluated the combination of tiragolumab and atezolizumab and suggests potential antitumor activity in NSCLC. Read More ›

Non-Small Cell Lung Cancer Coverage Brought to You By

AACR 2025 - Non–Small Cell Lung Cancer